Emicizumab

Therapeutic indications

Emicizumab is indicated for:

Routine prophylaxis of bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency)

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Emicizumab is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency):

with factor VIII inhibitors
without factor VIII inhibitors who have:
- severe disease (FVIII <1%)
- moderate disease (FVIII ≥1% and ≤5%) with severe bleeding phenotype.

Emicizumab can be used in all age groups.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

3 mg/kg once weekly for the first 4 weeks (loading dose), followed by a maintenance dose from week 5, of either 1.5 mg/kg once weekly, 3 mg/kg every 2 weeks, or 6 mg/kg every 4 weeks

Contraindications

Emicizumab is contraindicated in the following cases:

Lactation

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.